Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34496 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Romina Silva und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Irish Cancer Society, Science Foundation Ireland.
Abstract (Originalsprache)
Resistance to platinum‐based chemotherapy is the major cause of death from high‐grade serous ovarian cancer (HGSOC). We hypothesise that detection of specific DNA methylation changes may predict platinum resistance in HGSOC. Using a publicly available “discovery” dataset we examined epigenomic and transcriptomic alterations between primary platinum‐sensitive (n = 32) and recurrent acquired drug resistant HGSOC (n = 28) and identified several genes involved in immune and chemoresistance‐related pathways. Validation via high‐resolution melt analysis of these findings, in cell lines and HGSOC tumours, demonstrated the most consistent changes were observed in three of the genes: APOBEC3A, NKAPL and PDCD1 . Plasma samples from an independent HGSOC cohort (n = 17) were analysed using droplet digital PCR. Hypermethylation of NKAPL was detected in 46% and hypomethylation of APOBEC3A in 69% of plasma samples taken from women with relapsed HGSOC (n = 13), with no alterations identified in disease‐free patients (n = 4). Following these results, and using a CRISPR‐Cas9 approach, we were also able to demonstrate that in vitro NKAPL promoter demethylation increased platinum sensitivity by 15%. Overall, this study demonstrates the importance of aberrant methylation, especially of the NKAPL gene, in acquired platinum resistance in HGSOC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Biology and Therapeutics Laboratory, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
- Systems Biology Ireland, UCD School of Medicine, University College Dublin, Dublin, Ireland.
- School of Biology and Environmental Science, University College Dublin, Dublin, Ireland.
- UCD Gynaecological Oncology Group, UCD School of Medicine Mater Misericordiae University Hospital, Dublin, Ireland.
- Department of Pathology, St Vincent's University Hospital, Dublin, Ireland.
- Cancer Biology & Epigenetics Group, IPO Porto Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto /Porto Comprehensive Cancer Centre (Porto.CC…
ORCID-Profile: Romina Silva, Carmen Jeronimo
Förderung
- Irish Cancer Society
- Science Foundation Ireland
Zitieren
APA
Silva, R., Glennon, K., Metoudi, M., Moran, B., Salta, S., Slattery, K., Treacy, A., Martin, T., Shaw, J., Doran, P., Lynch, L., Jeronimo, C., Perry, A. S., & Brennan, D. J. (2023). Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer. International Journal of Cancer. https://doi.org/10.1002/ijc.34496
Vancouver
Silva R, Glennon K, Metoudi M, Moran B, Salta S, Slattery K, et al. Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer. International Journal of Cancer. 2023. doi:10.1002/ijc.34496
BibTeX
@article{Silva2023,
author = {Silva, Romina and Glennon, Kate and Metoudi, Michael and Moran, Bruce and Salta, Sofia and Slattery, Karen and Treacy, Ann and Martin, Terri and Shaw, Jacqui and Doran, Peter and Lynch, Lydia and Jeronimo, Carmen and Perry, Antoinette S and Brennan, Donal J},
title = {Unveiling the epigenomic mechanisms of acquired platinum‐resistance in high‐grade serous ovarian cancer},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34496}
}
EUVIMED